The drug discovery and development landscape is plagued by inefficiency, risk and astronomical cost. Clinical success rates languish below 10%, convoluted in- and out-licensing workflows erode precious patent life, and industry estimates suggest that biopharma companies write off some $15 billion every year on deprioritized candidates. At the same time, more than 90% of oncology drugs—and a significant proportion of all therapeutics—will lose patent exclusivity within the next five years, creating a looming innovation shortfall. Partex is here to bridge that gap. As the world’s largest artificial intelligence (AI)-driven drug-asset manager, Partex supercharges pipelines, resurrects shelved compounds and slashes development time to clinic—revolutionizing discovery and development at every step.
From data ocean to drug assets
At the heart of Partex lies an unparalleled ocean of real-time data—650 terabytes of public sources, 270 terabytes of proprietary studies and more than 2 million de-identified patient records—which are continuously updated and fully auditable (Fig. 1). More than 200 specialized AI models roam this data landscape, rapidly delivering actionable insights across the entire research and development (R&D) continuum.
Fig. 1 | Converting data to actionable insights. Specialized AI models scour an ocean of data to accelerate drug discovery and development. IP, intellectual property.
This enables target discovery and repurposing by uncovering hidden indications or rewiring old molecules for new applications; clinical trial optimization by predicting enrolment bottlenecks, forecasting safety signals and adapting trial designs on the fly; and asset valuation and licensing through quantifying pipeline value, matching deprioritized assets with ideal partners and accelerating deal flow.
Unlike closed-box systems, Partex’s platform provides end-to-end transparency. Every data source, model run and recommendation is traceable, so partners and even patients—through data partnerships with the German Working Group on Internal Oncology (AIO), for example—can see exactly how and why decisions are made.
“Life science is awash with disconnected datasets and siloed expertise,” said Gaurav Tripathi, co-founder and CTO of the Partex Group company Innoplexus. “We unify public, private and real-world data under one governed framework, giving researchers and clinicians unprecedented clarity and control.”
A portfolio of partnered and in-house assets
Partex offers a fully managed service that prunes and enriches biopharma pipelines, unlocking latent value at near-zero risk. “We help our partners extract every ounce of potential from their active and archived assets,” explained Frank Grams, chief commercial officer at the Partex Group. “Whether in-licensing high-fit candidates or out-licensing deprioritized molecules, we tailor each engagement to strategic objectives.”
Concurrently, Partex scouts late-stage preclinical compounds for its own portfolio, developed under the Cureteq umbrella. Oncoteq, a Cureteq-backed clinical-stage biotech, is already advancing novel therapies in renal-cell carcinoma, tumor necrosis factor receptor superfamily member 8 (CD30)-expressing malignancies and estrogen-receptor-positive breast cancer.
Global partnerships and next-gen foundation model
To date, more than 50 leading biopharma organizations rely on Partex, and 30 risk-sharing partnerships are in flight. With bases in Europe and India, and a rapid expansion in North America, Partex collaborates with pharma, biotech, contract research organizations (CROs), academic medical centers and even patient-advocacy groups to co-create value.
In 2023, Partex enabled Sanofi to reposition a gastrointestinal asset in record time, and today it is guiding Fortress Biotech in Miami through a multi-asset licensing evaluation. Meanwhile, in collaboration with top hospitals, Partex is deploying the largest real-world data foundation model ever assembled: a purpose-built AI engine trained on diverse patient records to power clinical-decision support, predictive safety monitoring and interactive research assistants. This foundation model is one application layer atop the broader Partex platform—designed not only for chat interfaces, but also for seamless integration into workflows across R&D, medical affairs and regulatory affairs.
“By weaving together data, AI and blockchain-grade transparency, we’re turning drug development into a high-velocity, low-risk engine for innovation,” said Partex’s founder and CEO Gunjan Bhardwaj. “Our mission is audacious: to halve the time and cost of bringing new therapies to patients worldwide.”
With its unprecedented data scale, sophisticated AI architecture, leading patent position and collaborative business model, Partex stands ready to reshape the future of medicine—delivering better drugs, faster and more transparently than ever before.